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Abstract
Purpose: Real-time intraoperative near-infrared fluorescence (NIRF) imaging is a promising
technique for lymphatic mapping and sentinel lymph node (SLN) detection. The purpose of this
technical feasibility pilot study was to evaluate the applicability of NIRF imaging with indocyanin
green (ICG) for the detection of the SLN in cervical cancer.
Procedures: In ten patients with early stage cervical cancer, a mixture of patent blue and ICG
was injected into the cervix uteri during surgery. Real-time color and fluorescence videos and
images were acquired using a custom-made multispectral fluorescence camera system.
Results: Real-time fluorescence lymphatic mapping was observed in vivo in six patients; a total
of nine SLNs were detected, of which one (11%) contained metastases. Ex vivo fluorescence
imaging revealed the remaining fluorescent signal in 11 of 197 non-sentinel LNs (5%), of which
one contained metastatic tumor tissue. None of the non-fluorescent LNs contained metastases.
Conclusions: We conclude that lymphatic mapping and detection of the SLN in cervical cancer
using intraoperative NIRF imaging is technically feasible. However, the technique needs to be
refined for full applicability in cervical cancer in terms of sensitivity and specificity.
Key words: Cervical cancer, Near-infrared fluorescence, Sentinel lymph node, Multispectral
intraoperative imaging
Abbreviations: ICG, Indocyanin green; LN, Lymph node; NIR, Near-infrared; NIRF, Near-infrared
fluorescence; SLN, Sentinel lymph node
Introduction
O
ver the last decades, the sentinel lymph node (SLN)
concept has proven feasible and safe in selected types
of cancer such as vulvar cancer, breast cancer, early gastric
cancer, and melanoma [1–5]. Recently, intraoperative near-
infrared fluorescence (NIRF) imaging was developed as a
novel technique for SLN detection. By using a NIR
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umcg.nlfluorescent dye such as indocyanin green (ICG) and a
sensitive fluorescence camera system, intraoperative lymph
node mapping has been proven feasible in breast cancer and
skin cancer patients, with comparable to or slightly better
detection rates than conventional techniques [6–9]. Advan-
tages of this technique are the real-time feature for lymphatic
mapping and the avoidance of radioactivity. Furthermore,
the one-step procedure of NIRF imaging takes place entirely
during surgery, thus improving patient comfort. To date,
NIRF imaging has not been applied in cervical cancer.
The prognosis of early stage cervical cancer is substan-
tially influenced by lymph node (LN) status, with positive
LNs adding to an unfavorable prognosis [10, 11]. Standard
surgical treatment therefore consists of radical hysterectomy
combined with bilateral pelvic lymphadenectomy. Metastatic
involvement is found in no more than 13–27% of the LNs
[1, 11], implying that radical pelvic lymphadenectomy can
be regarded as overtreatment without clinical benefit in more
than three quarters of the patients. Moreover, LN dissection
may have the unfavorable consequence of lymphedema of
the legs, occurring in 14–32% of patients [12, 13]. The SLN
procedure could lead to more selective LN dissection, but its
definitive value in cervical cancer is still a matter of debate
and subject of ongoing investigation. The reliability in terms
of sensitivity has improved markedly in the last two decades,
mainly due to the combination of a radioactive tracer
combined with a blue dye rather than using blue dye alone
[14]. This bimodal approach yields false negative rates of
0% in tumors G2c m[ 15, 16]. Although these data are
encouraging, SLN detection in the pelvic region remains
complicated due the bilateral and not fully predictable
lymphatic routing originating from the uterine cervix. About
80% of SLNs are found in the area of internal and external
iliac nodes and in the obturator fossa, but involvement of
lymph nodes in the parametrium and para-aortal regions has
also been reported (Fig. 1)[ 17–20]. Bilateral SLNs are
found in 59–66% of patients [15, 16]. In particular, the blue
dye can be difficult to trace in extrapelvic areas because of
overlying muscle tissue or fat.
A great advantage of NIRF imaging over existing
techniques is the high target-to-background ratio. When
applied in cervical cancer, we hypothesized that real-time
NIRF intraoperative imaging could be advantageous in the
visualization of the drainage pattern and, thus, dynamic
detection of the SLN in the pelvic anatomy. We therefore
initiated this pilot study to evaluate the technical feasibility
and applicability of a clinical prototype intraoperative
fluorescence camera system for detection of the SLN in
cervical cancer.
Patients and Methods
Study Population
This pilot study was approved by the Institutional Review Board of
the University Medical Center Groningen and was performed in
accordance with the ethical standards of the Helsinki Declaration
of 1975 (Dutch Trial Register no. NTR1981, EudraCT no. 2009-
010560-42). Consecutive patients with a cervical cancer stage
IA1, IB1, or IIA, eligible for abdominal hysterectomy and pelvic
lymphadenectomy aged 21 years and older were included. They
were recruited by the gynecologist and/or the research physician
in the outpatient clinic. Informed consent was obtained after at
least 1 week of reflection time. All patient data were deperson-
alized. Exclusion criteria included severe renal failure (serum
creatinine ≥400 μmol/L), severe cardiac or pulmonary failure
(ASA III–IV), past or present hyperthyroidism, pregnancy, or a
previous severe allergic or anaphylactic reaction to insect bites
or medication.
Imaging System
The prototype intraoperative multispectral fluorescence camera
system used in this study (Fig. 2) was developed at the Helmholtz
Zentrum of the Technical University Munich, Germany (NJ, GT,
AS, VN) in close collaboration with SurgOptix (SurgOptix Inc.,
Redwood Shores, CA, USA). The system and its components were
recently extensively described by Themelis et al.[ 21] and will be
pointed out briefly.
A white light source illuminates the operating field and a
laser diode provides light of a desired wavelength for excitation
of the fluorescent probe. Light passes through a system of optics
and is separated into visible light (color), light at the emission
(fluorescence) wavelength band, and light at the excitation
wavelength band (intrinsic). These bundles are detected by
sensitive CCD cameras. Multispectral signals from all three
cameras are processed and combined in order to correct for
artifacts and yield true quantitative fluorochrome biodistribution.
Color and fluorescence signals can be displayed as separate
images on external monitors or superimposed in one image,
allowing for adequate anatomical positioning of the fluorescence
signal. Images and real-time videos up to 12 frames per second
Fig. 1. Lymph drainage of the cervix uteri is complex,
bilateral, and can affect lymph nodes in several areas. In
our pilot study, nine SLNs were found. These were localized
in the left obturator fossa (three), right obturator fossa (two),
left external iliac (one), right external iliac (one), right common
iliac (one), and on the junction of the right internal iliac and
obturator fossa (one).
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the color image and the fluorescence signal are presented on
external monitors, providing the surgeon with an unhindered
view. Sterile drapes are used in the operating room to cover the
camera system completely, making it applicable and safe for
intraoperative use. The technical service of the University
Medical Center Groningen performed necessary tests for leakage
current and safety of the application of the camera in its current
form during surgery.
Imaging Agents
Shortly prior to surgery, a vial of 25 mg ICG (Pulsion Medical
Systems AG, Munich, Germany) was dissolved in 50 mL of
water for injection (B. Braun Medical), yielding a concentration
of 0.5 mg/mL. This concentration has previously been described
adequate for SLN imaging [5]. For each patient, a new vial of ICG
was used because of degradation of the fluorescence signal of ICG
after dissolving. One milliliter of undiluted patent blue (Bleu patenté,
Guerbet, France) was mixed with 1 mL of dissolved ICG in a syringe
for injection into the cervix uteri and protected from light to prevent
bleaching.
Surgical Procedure
After laparotomy, the camera system was prepared for imaging
and moved above the operating field. In this setting, the lens of
the camera is situated approximately 25 cm above the patient.
Real-time video capturing was started simultaneously with or
shortly after the injection of the 2 mL mixture of ICG and
patent blue in four quadrants of the cervix uteri. Propulsion of
the ICG/patent blue mixture through the lymphatics was
followed real time. The first appearing LN was denominated
as the SLN. The SLN or—in the case of bilateral lymph flow—
multiple SLNs were removed and the fluorescence signal was
quantified ex vivo. Next, the remaining LNs in the obturator
fossa and in the internal, external, and communal iliac regions
were dissected and evaluated for fluorescence and blue
discoloration ex vivo. From this point on, surgery was carried
out following the standard procedure. In case no fluorescent
SLN was found in vivo, all LNs were dissected and evaluated ex
vivo for a possible fluorescent signal and/or blue discoloration.
All LNs were sent to the pathologist for histopathological
examination. In case of a fluorescent hot spot in a cluster of
LNs, the fluorescent node was excised and examined separately
for tumor involvement.
Results
Study Population
Demographic and clinical characteristics are shown in
Table 1. Ten patients were included in this pilot study
(mean age 51.3, range 39–74; mean BMI 22.7, range 15–
30). The majority of patients was diagnosed with stage IB1;
five patients had a tumor G2 cm. No side effects were
reported following the injection of ICG and patent blue.
Histopathological examination revealed three patients with
adenocarcinoma and seven with squamous carcinoma of the
cervix. This is concordant with incidence rates in the
population [22, 23].
Intraoperative Fluorescence Imaging
The fluorescent signal in the lymphatics became visible
within 30 s upon injection of ICG and patent blue, with the
SLN generally appearing within 1–2m i n( E S MSupplemental
Video 1). Lymphatic mapping was clearly discernible in vivo in
six patients (nos. 1, 3, 4, 5, 7, and 9). In one of these patients
(no. 7), the lymph vessels were visible, but no SLN appeared. In
contrast, no lymph vessels were visible in one patient (no. 10);
nevertheless, the SLN could easily be detected in vivo. This case
is illustrated in Fig. 3. In total, one or more SLNs were detected
in six patients (nos. 1, 3, 4, 5, 9, and 10). In these patients, a total
number of nine SLNs were detected. A bilateral SLN was
detected in three patients. The SLNs were located in the left
Fig. 2. Camera system wrapped in sterile drapes in the
operating theater.
Table 1. Demographics and results
Study no. Age BMI FIGO stage Tumor type
a Tumor size
1 41 19 IB1 Squamous No tumor
left after LEEP
2 70 26 IB1/IIA Squamous 92c m
3 48 24 IB1 Squamous 92c m
4 40 24 IA2 Adeno G2c m
5 40 22 IB1 Adeno 92c m
6 40 20 IB1 Adeno No tumor
left after LEEP
7 70 23 IB1 Squamous 92c m
8 74 24 IB2 Squamous 92c m
9 39 15 IB1 Squamous G2c m
10 51 30 IB1 Squamous G2c m
aHistologic subtype: squamous cell carcinoma (squamous)o r
adenocarcinoma (adeno)
BMI body mass index, FIGO International Federation of Gynecology and
Obstetrics, LEEP loop electrosurgical excision procedure conization
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iliac (one), right external iliac (one), right common iliac (one),
and on the junction of the right internal iliac and obturator fossa
(one, Fig. 1). Of these nine fluorescent SLNs, six also showed a
blue discoloration. Ex vivo fluorescence imaging confirmed the
strong fluorescent signal in all excised SLNs. One of the SLNs
turned out to contain metastatic disease on histopathological
examination. A summary of the results is shown in Table 2.
Infourpatients,nolymphaticmappingcouldbeobservedin
vivo. Three of these patients had tumors 92 cm. In patient 2,
intra-abdominal fat impeded detection of fluorescence. How-
ever, upon dissection, a blue LN was discovered in the
obturator fossa, also showing a strong fluorescent signal ex
vivo. On histopathological examination, this LN turned out to
contain metastatic tumor tissue. In patient 6, a smaller
abdominal incision prevented maximal exposure of all the
LN basinstothe camera, thushampering detection. Leakage of
ICG and patent blue into the pelvis as a result of a deep
intracervical injection prevented SLN detection in patient 7.
The last patient (no. 8) in whom no SLN could be detected in
vivo was initially diagnosed with stage IB1 cervical cancer, but
was upstaged to IB2 during surgery, a stage that does not
strictly apply to the inclusion criteria. The size of the tumor
could be the cause of hampered lymph flow and concomitant
fluorescent and blue agents through the lymphatics.
Ex vivo Fluorescence Imaging
After LN dissection, all excised LNs were imaged for
fluorescence ex vivo (Tables 2 and 3). A total of 197 non-
sentinel LNs were taken out, with a mean number of 20 LNs
per patient (range 10–27).
In the six patients in whom SLN(s) were detected in vivo,
a total of 116 non-sentinel LNs were excised. None of these
contained metastases. In four of these six patients, a total of
six LNs were found to show a fluorescent signal on ex vivo
imaging; none of these were blue. The localization of these
fluorescent LNs was in two cases contralateral from the SLN
(patients 9 and 10; Table 3).
In the four patients in whom no SLN wasdetected in vivo,81
LNsweretakenout.FiveLNsshowedafluorescentsignal;three
of these were also blue. An example of ex vivo fluorescence in a
cluster of lymph nodes is shown in Fig. 4. Bilateral fluorescent
LNswerefoundinpatient2.OnlyoneoftheseLNs,whichwere
both fluorescent and blue, turned out to contain metastases.
None of the non-fluorescent LNs contained metastases.
In summary, one of nine SLNs (11%) contained
metastases. Eleven of 197 non-sentinel LNs (5.6%) showed
a fluorescent signal ex vivo; three of these (1.5%) were also
blue. One of these fluorescent non-sentinel LNs contained
metastases.
Discussion
This pilot study is, to our knowledge, the first clinical study
to assess the technical feasibility of NIRF for the detection
of the SLN in cervical cancer. We show that lymphatic
mapping and SLN detection using the fluorescent contrast
agent ICG is technically feasible. One or more SLNs were
found in six out of ten patients; bilateral SLNs were detected
Fig. 3. In vivo fluorescence imaging of a lymph node. a Color image. b Fluorescence image. c Overlay of the pseudocolor
fluorescent signal on top of the color image.
Table 2. Summary of in vivo and ex vivo results
SLN detected in vivo SLNs fluorescent
a SLNs blue
b SLN metastasis
c LNs dissected LNs fluorescent
d LNs blue
e LN metastasis
f
Yes (n=6) 9 6 1 116 6 0 0
No (n=4) n/a n/a n/a 81 5 3 1
Total (n=10) 9 5 1 (11%) 197 11 3 1 (0.5%)
aNumber of SLNs showing fluorescence in vivo
bNumber of SLNs showing a blue discoloration
cNumber of SLNs that were confirmed to contain metastatic tumor tissue
dNumber of non-sentinel LNs showing fluorescence ex vivo
eNumber of LNs showing a blue discoloration ex vivo
fNumber of LNs that were confirmed to contain metastatic tumor tissue
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fluorescence imaging was more straightforward in lean
patients in whom the pelvic lymph basins could be more
easily exposed and somewhat more difficult in obese
patients. Use of the intraoperative camera system in itself
did not hinder the surgeon, and the surgical procedure was
not extended with more than 30 min due to imaging.
However, the limited range of movement of the camera head
combined with smaller surgical incisions caused difficulties
in the detection of fluorescence in deep areas of the pelvis.
A number of summarized studies report detection of one
or more SLNs in early stage cervical cancer in 84–97% of
patients using radiocolloid in combination with blue dye
[24–27]. The lower detection rate of 60% in our pilot study
can be explained by a number of factors, i.e., patient
characteristics, the learning curve concerned with the new
technique, and technical features of the camera system and
the fluorescent agent.
Several studies report that the SLN technique is less
applicable in patients with cervical tumors 92 cm, with
detection rates decreasing to 67–77% [24, 28]. This could be
the result of extensive tumor growth, causing either
embolization or mass blocking of the lymph vessels.
Consistent with literature, we observed better detection
rates in tumors smaller than 2 cm. SLNs were found in four
out of five patients with tumors G2 cm (80%) and in only
two out of five patients with tumors 92 cm (40%). Bilateral
SLNs were detected in two tumors G2 cm (40%) and in one
tumor 92 cm (20%). Furthermore, in one patient who
presented with a large tumor (stage IB2, patient 8), neither
the fluorescent nor the blue agent could be located in vivo in
the pelvis of ex vivo in dissected LNs, indicating that the
agents were not carried from the tumor into the lymphatics
toward the SLN or LNs. Although these data suggest
support for existing literature regarding the impact of tumor
size on (bilateral) SLN detection, our numbers are too small
to draw definitive conclusions from.
The detection rate of 60% observed in this pilot study may
furthermore be influenced by the learning curve of working
with the intraoperative camera system and correct injection of
the fluorescent agent. As gynecologic oncologists got more
acquainted with the technique and the injection, the procedure
Table 3. Localization of fluorescent sentinel lymph nodes in vivo and fluorescent non-sentinel lymph nodes ex vivo
Study no. No. of SLN(s) Localization SLN(s)
a SLNs with
metastasis
No. of fluorescent
LN(s) ex vivo
Localization fluorescent LNs
b LNs with
metastasis
c
1 2 Obturator left 0 0 – 0
Obturator right
20 –– 1 Obturator right 1
3 2 External iliac left 0 1 Junction external/common
iliac right
0
External iliac right
4 2 Obturator left 0 2 External iliac right 0
Obturator right Obturator right
5 1 Obturator left 1 0 – 0
60 –– 1 External iliac left 0
70 –– 3 External iliac left (2) 0
External iliac right
80 –– 0 – 0
9 1 External iliac right 0 2 Obturator left 0
Common iliac right
10 1 Common iliac right 0 1 External iliac left 0
aLocalization in vivo where the SLN(s) was found
bInitial localization of LNs that showed fluorescence ex vivo after dissection
cNumber of LNs showing fluorescence ex vivo that were confirmed to contain metastatic tumor tissue
Fig. 4. Ex vivo fluorescence imaging of a cluster of lymph nodes. a Color image. b Fluorescence image. c Overlay of the
pseudocolor fluorescent signal on top of the color image. This fluorescent lymph node did not contain metastases.
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was detected in vivo; however, when exposing the obturator
lymph basin better, a blue LN was found, which turned out to
be fluorescent as well. In retrospect, we believe that this LN
would have been detected as the SLN had we better exposed
the lymph basin. In two of three patients with a unilateral SLN,
we observed fluorescence ex vivo in a contralaterally located
LN. These findings indicate that in these patients, although the
fluorescent agent was transported bilaterally from the uterine
cervix; not all SLNs were detected. More experience with the
technique may lead to a higher detection rate of SLNs in vivo.
Apart from patient selection and learning curve, we
encountered several technical aspects influencing our results.
Deep-lying LNs were in some cases difficult to visualize due
to the limited range of movement of the camera head. A
smaller, more flexible, preferably handheld camera system
or even a laparoscopic system for intraoperative fluorescence
imaging could overcome this problem. Technical progress
will undoubtedly lead to more ergonomic and clinically
suited camera systems.
The most important limitation, however, appeared to be
the penetration depth of ICG which lies around 1 cm. This is
sufficient for superficial LNs, but generally not enough to
visualize lymph nodes covered by adipose tissue or located
deep in the pelvis hidden by the iliac vessels. In the current,
still limited range of FDA-approved fluorescent agents, none
has a larger penetration depth than ICG. In order to improve
fluorescence imaging in the pelvis, future developments
should be aimed at designing fluorescent agents with
stronger tissue-penetrating properties.
Apart from these pitfalls, fluorescence imaging also bears
several advantages. The most important benefit for patients
is that the fluorescent agent is injected in a one-step
sequence during surgery, when the patient is already
anesthetized, thus preventing four injections in the cervix
several hours or even a day prior to surgery, as is necessary
when using a radiocolloid. Furthermore, we observed that
the fluorescence signal is well discernable in the pelvic
anatomy as long as the desired region of interest is projected
within the field of view of the camera system. As mentioned
earlier, more flexible camera systems with a greater range of
movement will most certainly yield more optimized detec-
tion in deeper seated areas. Although the penetration depth
of NIR fluorescent agents will not exceed 1 cm, fluorescence
is easy to locate in the pelvic region when compared to
detection of the blue dye by visual inspection. Additionally,
the real-time video properties aid the gynecologic oncologist
in dynamic tracing of lymph flow toward the SLN within
minutes after injection into the cervix. This unique feature of
NIRF imaging provides a real-time image of the location and
flow of the fluorescent agent in the lymphatic system, in
close relation to the adjacent anatomical structures. This
would, to our opinion, be the major advantage of NIRF
imaging over conventional SLN detection methods. Future
NIR fluorescent agents with better penetration properties are
needed to improve detection rates.
Conclusion
We show that NIRF imaging using ICG for the detection of
the SLN in early stage cervical cancer is technically feasible.
Advantages of this approach are the real-time tracing of
lymph flow and the one-step procedure. However, technical
improvements and fluorescent dyes with larger penetration
strength are needed to refine the technique.
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